Do you use metabolic risk (e.g., diabetes and significant fibrosis) as an exclusion criterion for nucleos(t)ide analogue cessation even when virologic stopping criteria are met, and if so what specific metabolic/fibrosis thresholds constitute a ‘veto’ in your practice?